4//SEC Filing
Kooij Louise Frederika 4
Accession 0000950170-24-110955
CIK 0001936258other
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 5:23 PM ET
Size
9.1 KB
Accession
0000950170-24-110955
Insider Transaction Report
Form 4
Kooij Louise Frederika
Chief Accounting Officer
Transactions
- Exercise/Conversion
Option (right to buy)
2024-09-27−45,000→ 168,073 totalExp: 2031-07-06→ Ordinary Shares (45,000 underlying) - Sale
Ordinary Shares
2024-10-01$15.72/sh−45,000$707,400→ 0 total - Exercise/Conversion
Ordinary Shares
2024-09-27+45,000→ 45,000 total
Footnotes (3)
- [F1]The exercise price of the option is EUR 1.16392.
- [F2]The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.
- [F3]The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Documents
Issuer
NewAmsterdam Pharma Co N.V.
CIK 0001936258
Entity typeother
Related Parties
1- filerCIK 0002004379
Filing Metadata
- Form type
- 4
- Filed
- Sep 30, 8:00 PM ET
- Accepted
- Oct 1, 5:23 PM ET
- Size
- 9.1 KB